Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 10/20 | 0.41 |
| ▸ | OGA | O60502 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CDK4 | P11802 | 5/20 | 0.39 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18291587 | 0.83 | HRH4 (0.46) | HRH4OGAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20037523 | 0.83 | OGA (0.43) | HRH4OGAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL13768899 | 0.81 | KMT2A (0.59) | MEN1KMT2ASMN1; SMN2PTPN11LMNA | |
| SCHEMBL20249235 | 0.78 | HRH4 (0.48) | HRH4MEN1KMT2ASMN1; SMN2CDK4 | |
| SCHEMBL3826525 | 0.78 | LMNA (0.43) | OGAMEN1KMT2ASMN1; SMN2CDK4 | |
| SCHEMBL3828733 | 0.78 | CYP1A2 (0.46) | HRH4OGAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25104869 | 0.78 | HRH4 (0.37) | HRH4OGA | |
| SCHEMBL31713990 | 0.78 | HRH4 (0.37) | HRH4OGA | |
| SCHEMBL30228927 | 0.78 | HRH4 (0.37) | HRH4OGA | |
| SCHEMBL31714098 | 0.78 | HRH4 (0.37) | HRH4OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| EP-3305785-A1 | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Teijin Pharma Limited (JP) | 2018-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | HRH4 1763/4885OGA 4627/4885MEN1 2609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.